White Papers

Beyond Stigma and Scripts: What the System Gets Wrong About Obesity Care

05/07/2026

In one of the largest surveys of its kind, Omada polled more than 3,000 people who have used GLP‑1s for weight loss, offering a timely view of how the GLP‑1 experience is evolving and where the.

Optimizing The Quantity and Quality of GLP-1 Weight Loss: Evidence from a 12-Week Comparative Study

04/10/2026

GLP‑1 medications have changed what’s possible for weight loss, but they also raise a critical question: what are people losing—fat, lean mass, or both? Omada’s Insights Lab conducted a 12‑week.

GLP-1s are Changing Americans’ Bodies–But Not in the Way You Think

02/11/2026

Demand for GLP-1 agonists has been steadily climbing. From 2019 to 2023, the number of patients without diabetes who started GLP-1 treatment for obesity rose 700%; and demand for these ‘miracle’.

Webinars & Events

The Story Between Visits: A New Lens on Cardiometabolic Care

06/03/2026

Cardiometabolic care is often discussed through the lens of prevalence, cost, and employer burden, but those data points often do not fully explain why many people struggle to sustain progress across.

NEBGH Cardiometabolic Health as a Business Imperative

03/16/2026

We’re thrilled to join the NEBGH Cardiometabolic Health as a Business Imperative Conference for the first time. This event brings together senior HR, benefits, and healthcare leaders for a strategic.

HLTH: 2026 Sponsor

02/24/2026

We’re proud to return as a sponsor of HLTH 2026 in Las Vegas. As the premier event for healthcare innovation, HLTH brings together more than 12,000 leaders, executives, and visionaries shaping the.

Keep Browsing

See All Posts
Become an Omada Insider
Sign Up